ab14500 AGPAT5 Antibody
品牌 |
|
|---|---|
产品货号 |
|
来源种属 |
Rabbit |
抗体克隆 |
Polyclonal |
来源亚型 |
IgG |
实验方法 |
WB,IHC,IF,ICC |
实验种属 |
Human,Mouse,Rat,Rabbit,Pig,Dog,Chicken,Bovine,Horse,Sheep |
偶联标记 |
Unconjugated |
目的蛋白 |
AGPAT5 |
产品规格 |
50μl,100μl,200μl |
产品报价 |
¥1500/¥2750/¥3600 |
实验应用
Western blotting
Recommended dilution: 1:500-1000
Immunofluorescence
Recommended dilution: 1:100-1:500
immunocytochemistry
Recommended dilution: 1:100-1:500
Immunohistochemistry
最佳稀释倍数与浓度应由实验研究人员确认
产品说明
产品背景
Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Acts on LPA containing saturated or unsaturated fatty acids C15:0-C20:4 at the sn-1 position using C18:1-CoA as the acyl donor. Also acts on lysophosphatidylethanolamine using oleoyl-CoA, but not arachidonoyl-CoA, and lysophosphatidylinositol using arachidonoyl-CoA, but not oleoyl-CoA. Activity toward lysophosphatidylglycerol not detectable.Description
Rabbit polyclonal antibody to AGPAT5
Applications
WB, IF, ICC, IHC.
Immunogen
AGPAT5 Antibody detects endogenous levels of total AGPAT5.
Reactivity
Human, Mouse.
可预测：Horse(86%), Dog(%)
Molecular weight
45 KD; 42kD(Calculated).
Host species
Rabbit
Ig class
Immunogen-specific rabbit IgG
Purification
Antigen affinity purification
Full name
AGPAT5
Synonyms
1 acyl sn glycerol 3 phosphate acyltransferase epsilon; 1 acylglycerol 3 phosphate O acyltransferase 5; 1 AGP acyltransferase 5; 1 AGPAT 5; 1 AGPAT5; 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon; 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1-acylglycerol-3-phosphate O-acyltransferase 5; 1-AGP acyltransferase 5; 1-AGPAT 5; 1acylglycerol3phosphate Oacyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1acylglycerol3phosphate Oacyltransferase 5; 1acylglycerol3phosphate Oacyltransferase5 (lysophosphatidic acid acyltransferase, epsilon); 1AGP acyltransferase 5; 1AGPAT5; AGPAT5; LPAAT e; LPAAT epsilon; LPAAT-epsilon; LPAATE; Lysophosphatidic acid acyltransferase epsilon; PLCE_HUMAN;
Storage
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Swissprot
Q9NUQ2
产品图片
|
|
Western blot analysis of extracts from Mouse liver, using AGPAT5 Antibody. The lane on the left was treated with blocking peptide. |
|
|
Western blot analysis of extracts from Hela, using AGPAT5 Antibody. |
|
|
ab14500 at 1/100 staining Human pancreatic cancer and adjacent nomal tissues by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the primary antibody at 4°C overnight. An HRP conjugated anti-Rabbit antibody was used as the secondary antibody. |
|
|
Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs: |
|
|
Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs: |
